[This review was originally posted at the Nieman Journalism Lab Order Glucophage, on Sept. 9, 2011.]

TechCrunch, ethics, and new notions of journalism: The prominent tech news site TechCrunch tends to find itself in the middle of some controversy or another fairly regularly. Usually they're relatively inconsequential inside baseball, but this week's blowup is by far its biggest, and it spurred some enlightening discussion outside of the tech-news bubble, canada, mexico, india.

Here's the quick summary of what happened (the Guardian has a fuller version): Michael Arrington, TechCrunch's founder and editor, launched a venture capital fund to invest in tech companies — the same companies TechCrunch covers. AOL, which bought the site last year, responded by taking him off of TechCrunch and moving him to the business side in an arrangement that no one completely understood. Arrington fired back with an ultimatum: Give TechCrunch total editorial freedom, or sell it back to him, Order Glucophage. Effects of Glucophage, AOL has reportedly countered by booting Arrington entirely. Whatever happens, TechCrunch's MG Siegler said the site won't likely be the same.

There were conflicting views on the impact of Arrington's reported ouster, of course — Reuters' Felix Salmon said AOL is losing its top journalist, while Fortune's Chadwick Matlin said the fall of TechCrunch would be good for the tech industry. But the central issue here was the ethics of Arrington's arrangement — investing in the same companies his site covers, something he's been doing openly for years, real brand Glucophage online.

The critique was articulated most strongly by the New York Times' David Carr Order Glucophage, , who documented several instances of TechCrunch writing favorable pieces on companies in which Arrington had invested, calling the arrangement "almost comically over the line." All Things Digital's Kara Swisher delivered an angrier version — "A giant, greedy, Silicon Valley pig pile" — and many others were also critical, including the Atlantic's Alexis Madrigal, Rem Rieder of the American Journalism Review, and VentureBeat's Dylan Tweney.

TechCrunch had its defenders, too, including Gawker's Ryan Tate, who argued for the hypocrisy of AOL's Arianna Huffington's sudden concern about ethics. The most thorough defenses, though, Glucophage coupon, came from TechCrunch's writers themselves: First, Paul Carr asserted that the new company would have nothing to do with TechCrunch. Then, both Carr and MG Siegler responded to David Carr's column by arguing that their site doesn't have the editorial workflow that its critics assume, and by criticizing the Times for its own ethical conflicts. "Ultimately there is only one thing that matters: information. People don’t care how they get it, just that they get it. If they don’t think they can trust it from one source, they’ll find another way to get it," Siegler wrote, Order Glucophage.

Some observers, buy cheap Glucophage no rx, like New York mag's Chris Rovzar, called that defense naive. In a terrific post here at the Lab, j-prof C.W. Anderson looked a bit deeper into the ways TechCrunch's philosophy challenges traditional journalism's norms, particularly the site's commitment to transparency as its primary ethical safeguard and its idea of the supremacy of information. About Glucophage, There was also the question of whether Arrington should have to abide by journalistic standards in the first place. Arrington asserted Order Glucophage, that he's not a journalist, and tech pioneer Dave Winer argued that "journalism itself is becoming obsolete." GigaOM's Mathew Ingram countered that journalism is still alive, just evolving and expanding, and j-prof Jeff Jarvis said journalism defies definition, and that's just fine.

—

A bigger challenge for Digital First: John Paton has grabbed a lot of attention with his rejuvenation of the formerly bankrupt newspaper chain the Journal Register Co., and this week, his project expanded to include a much larger (also formerly bankrupt) company, MediaNews Group, which owns papers such as the Denver Post, St. Paul Pioneer Press, Glucophage gel, ointment, cream, pill, spray, continuous-release, extended-release, and Detroit News. Though the two companies will remain formally separate, Paton will manage both companies under the auspices of the newly created Digital First Media.

Paton briefly reiterated his digitally centered philosophy in a blog post on the move, and GigaOM's Mathew Ingram called him the "patron saint" of the digitally focused, open approach to newspapers, Buy Glucophage no prescription, as opposed to the more print-protectionist, paywall-oriented one. Reuters' Felix Salmon said Paton's model of leveraging local sales staff and trusted editorial content for digital revenue makes much more sense than the hyperlocal-en-masse Patch model, Order Glucophage.

There's another important aspect to this deal, though: the Journal Register Co. was bought this summer by Alden Global Capital, a hedge fund that also owns a significant stake in MediaNews and several other newspaper companies. The Lab's Joshua Benton provided some background on that situation, and Ken Doctor predicted that the move "may mark just the beginning of a local newspaper roll-up, Glucophage cost, resulting in the United States’ first truly national local news(paper) company," noting that Paton's Digital First initiative is also accompanied by major cost-cutting. At the Knight Digital Media Center, Amy Gahran expressed concern that Paton's plans could run aground on an entrenched traditional culture at MediaNews and the impatience of hedge-fund investors. Order Glucophage, MediaNews also has newly installed paywalls at 23 papers, and Paton told paidContent he isn't sure yet what will happen to them. But one change has already been made: MediaNews' contract with copyright litigant Righthaven has been ended.

—

WikiLeaks under fire: We talked last week about the inadvertent release of the rest of WikiLeaks' archive of 251, Glucophage pharmacy, 000 diplomatic cables and the fallout that ensued. As it happened, WikiLeaks decided late last week to go ahead and publish all of the unredacted cables themselves, given that they had already been leaked online.

The decision led to more criticism — not just from the traditional media, but from others on the web: the Personal Democracy Forum's Micah Sifry, author of a book on WikiLeaks, chastised the organization for the dump, online buy Glucophage without a prescription, saying it's thrown away the moral high ground. Consultant Tom Watson said WikiLeaks' move has damaged their efforts at transparency and an empowered society, and James Ball, a former WikiLeaks volunteer, made the same point more powerfully by painting a picture of an internal culture at odds with the group's stated ideals of accountability and openness. "WikiLeaks has done the cause of internet freedom – and of whistleblowers – more harm than US government crackdowns ever could," he said, Order Glucophage.

Tech blogger Dave Winer, however, After Glucophage, was more troubled by the traditional media's eagerness to blame and ostracize Assange for the incident. It's not about one person, he said, it's about the technology that makes WikiLeaks possible: "They have a method that they have religious feelings about, ones that some of us don't share, and that method is broken by the Wikileaks model." Mediaite's Frances Martel, meanwhile, wondered why no one seemed to care about the documents themselves, herbal Glucophage.

—

Yahoo fires its CEO: After a tumultuous two-and-a-half-year tenure, Yahoo CEO Carol Bartz was fired this week. The next step for the troubled Internet giant could be to engineer a sale, as CNNMoney's Paul La Monica urged it to do. Order Glucophage, Plenty of names were tossed around as potential buyers, most recently Yahoo co-founder Jerry Yang.

The Wall Street Journal detailed what's gone wrong at Yahoo, and Om Malik of GigaOM was one of many who pinned many of the company's failings on its board. Glucophage reviews, Malik called for Yahoo to rid itself of everything that connects it to the Internet's past, and Business Insider's Pascal-Emmanuel Gobry advised Yahoo to "own the fact that it's a media and content company," encouraging a strategy that looks quite similar to AOL's. PaidContent's David Kaplan noted that Yahoo has a lot of ground to make up in display advertising, and Mark Walsh of MediaPost wondered if we'll see more of an emphasis on mobile media from Yahoo now.

—

Reading roundup: Just a couple more items for this week:

— One piece of news to note: Google has killed FastFlip, the magazine-like news presentation tool it launched in 2009.

— As we continue to move closer to bona fide campaign season, Glucophage maximum dosage, the Columbia Journalism Review's Greg Marx offered a smart response to Jay Rosen's critique of political journalism last week, defending the usefulness of certain kinds of the much-maligned "horse-race journalism."

— On the practical side, Florida j-prof Mindy McAdams put together a handy list of 10 tips to compelling visual storytelling. It's a great resource for professionals, j-profs, and students.

Similar posts: Lipitor Cost. Cephalexin No Rx. Buy Retin A No Prescription. Armour results. Synthroid price, coupon. Armour price, coupon.
Trackbacks from: Order Glucophage. Order Glucophage. Order Glucophage. Order Glucophage online overnight delivery no prescription. Buy Glucophage online no prescription. Glucophage price, coupon.

[This review was originally posted at the Nieman Journalism Lab Bactrim For Sale, on April 1, 2011.]

Putting the Times' pay plan in place: If you read last week's review, the first half of this week's should feel like déjà vu — lots of back-and-forth about the wisdom of The New York Times' new online pay plan, and some more hand-wringing about getting around that plan. If you want to skip that and get to the best stuff, I recommend Staci Kramer, David Cohn, and Megan Garber.

The Times launched its pay system Monday with a letter to its readers (snarkier version courtesy of Danny Sullivan), along with a 99-cent trial offer for the first four weeks and free access for people who subscribe to the Times on Kindle, Bactrim price. Times digital chief Martin Nisenholtz gave a launch-day talk to newspaper execs, highlighted by his assertion that the link economy is not a win-win for content producers and aggregators.

Meanwhile, the discussion about the paywall's worth rolled on. You can find a good cross-section of opinions in this On Point conversation with Ken Doctor, the Journal Register's John Paton, The Times' David Carr, and NYTClean creator David Hayes, Bactrim For Sale. The plan continues to draw support from some corners, Get Bactrim, including The Onion (in its typically ironic style, of course) and PC Magazine's Lance Ulanoff. Former Financial Times reporter Tom Foremski and Advertising Age columnist Simon Dumenco both made similar arguments about the value of the plan, where can i buy cheapest Bactrim online, with Foremski urging us to support the Times as a moral duty to quality journalism and Dumenco ripping the blogosphere's paywall-bashers for not doing original reporting like the Times.

And though the opposition was expressed much more strongly the past two weeks, there was a smattering of dissent about the plan this week, too — some from the Times' mobile users. One theme among the criticism was the cost of developing the plan: Philip Greenspun wondered how the heck the Times spent $40 million on planning and implementation, and former Guardian digital head Emily Bell wrote about the opportunity cost of that kind of investment. Rx free Bactrim, BNET's Erik Sherman proposed that the Times should have invested the money in innovation instead.

A few other interesting thoughts about the Times' pay plan before we get to the wall-jumping debate: Media consultant Judy Sims said the plan might actually make the Times more social Bactrim For Sale, by providing an incentive for subscribers to share articles on social networks to their non-subscribing friends. Spot.Us' David Cohn argued that the plan is much closer to a donation model than a paywall and argued for the Times to offer membership incentives. And Reuters' Felix Salmon talked about how the proposal is changing blogging at the Times.

PaidContent's Staci Kramer said the Times is fighting an uphill battle in the realm of public perception, but that struggle is the Times' own fault, created by its way-too-complicated pay system.

—

The ethics of paywall jumping: With the Times' "pay fence" going into effect, Bactrim pictures, all the talk about ways to get around that fence turned into a practical reality. Business Insider compiled seven of the methods that have been suggested: A browser extension, Twitter feeds, using different computers, NYTClean and a User Script's coding magic, Google (for five articles a day), and browser-switching or cookie-deleting, Bactrim For Sale. Mashable came up with an even simpler one: delete "?gwh=numbers" from the Times page's URL.

Despite such easy workarounds, the Times is still cracking down in other areas: As Search Engine Land's Danny Sullivan noted, it blocks links from all Google sites after the five-articles-per-day limit is reached. Bactrim price, coupon, The Times also quickly (and successfully) requested a shutdown of one of the more brazen free-riding schemes yet concocted — NYT for a Nickel, which charged to access Times articles without paywall restrictions. (It did, however, let up on unauthorized Twitter aggregators of Times content.)

So we all obviously can crawl through the Times' loopholes, but should we. A few folks made efforts to hack through the ethical thicket of the Times' intentional and unintentional loopholes: Times media critic James Poniewozik didn't come down anywhere solid Bactrim For Sale, , but said the Times' leaky strategy "makes the paywall something like a glorified tip jar, on a massive scale—something you choose to contribute to without compulsion because it is the right thing" — except unlike those enterprises, it's for-profit. In a more philosophical take, the Lab's Megan Garber said the ethical conundrum shows the difficulty of trying to graft the physical world's ethical assumptions onto the digital world.

—

A possible +1 for publishers: Google made a big step in the direction of socially driven search this week with the introduction of +1, purchase Bactrim online, a new feature that allows users to vote up certain search results in actions that are visible to their social network. Here are two good explainers of the feature from TechCrunch and Search Engine Land, both of whom note that +1's gold mine is in allowing Google to personalize ads more closely, and that it's starting on search results and eventually moving to sites across the web.

The feature was immediately compared to Facebook's "Like" and Twitter's retweets, Bactrim no rx, though it functions a bit differently from either. As GigaOM's Mathew Ingram noted, because it's Google, it's intrinsically tied to search, which is both an advantage and a disadvantage. As Ingram said, it's smart to add more of a social component to search, but Google's search-centricity makes the "social network" aspect of +1 awkward, just as Buzz and Wave were, Bactrim For Sale. To paraphrase the argument of Frederic Lardinois of NewsGrange: if your +1's go into your Google Profile and no one sees them, do they really make a sound, generic Bactrim.

All this seems to be good news for media sites. Lost Remote's Cory Bergman said that if they essentially become "improve the SEO of this site" buttons, media companies will be pretty motivated to add them to their sites. Likewise, Poynter's Damon Kiesow reasoned that +1 could be a great way for media sites to more deeply involve visitors who arrive via Google, Bactrim duration, who have typically been less engaged than visitors from Facebook and Twitter.

—

Shrinking innovation to spur it: This month's Carnival of Journalism Bactrim For Sale, focuses on how to drive innovation, specifically through the Knight News Challenge and Reynolds Journalism Institute. Most of the posts rolled in yesterday, and they contain a litany of quick, smart ideas of new directions for news innovation and how to encourage it.

A quick sampling: City University London and Birmingham City University j-prof Paul Bradshaw proposed a much broader, smaller-scale News Challenge fund, with a second fund aimed at making those initiatives scale, where can i buy Bactrim online. J-Lab Jan Schaffer said we need to quit looking at innovation so much solely in terms of tools and more in terms of processes and relationships. British journalist Mary Hamilton and Drury j-prof Jonathan Groves both focused on innovation in training, with Groves proposing "innovation change agents" funded by groups like Knight and the RJI to train and transform newsrooms.

Also, University of British Columbia j-prof Alfred Hermida opined on the role of theory in innovation, Lisa Williams of Placeblogger advocated a small-scale approach to innovation, and the University of Colorado's Steve Outing had some suggestions for the RJI fellowship program, Bactrim For Sale.

—

The mechanics of Twitter's information flow: Four researchers from Yahoo and Cornell released a study this week analyzing, as they called it, Buy Bactrim no prescription, "who says what to whom on Twitter." One of their major findings was that half the information consumed on Twitter comes from a group of 20,000 "elite" users — media companies, celebrities, organizations and bloggers. As Mathew Ingram of GigaOM observed, that indicates that the power law that governs the blogosphere is also in effect on Twitter, and big brands are still important even on a user-directed platform, Bactrim no prescription.

The Lab's Megan Garber noted a few other interesting implications of the study, delving into Twitter's two-step flow from media to a layer of influential sources to the masses, as well as the social media longevity of multimedia and list-oriented articles. A couple of other research-oriented items about Twitter: A Lab post on Dan Zarrella's data regarding timing and Twitter posts, and Maryland prof Zeynep Tufekci wrote a more theoretical post on NPR's Andy Carvin and the process of news production on Twitter.

—

Reading roundup: Plenty of other bits and pieces around the future-of-news world this week:

— New York Times editor Bill Keller wrote a second column Bactrim For Sale, , and like his anti-aggregation piece a couple of weeks ago, this piece — about the value of the Times' impartiality and fact-based reporting — didn't go over well. Buy Bactrim without prescription, Reuters' Felix Salmon called him intellectually dishonest, Scott Rosenberg called him defensive, and the Huffington Post's Peter Goodman (a former Times reporter) said Keller misrepresented him.

— A few notes on The Daily: Forbes' Jeff Bercovici said it was downloaded 500,000 times during its trial period and has 70,000 regular users, and a study was conducted finding that it's more popular with less tech-savvy, purchase Bactrim for sale, less content-concerned users.

— Journal Register Co. CEO John Paton talked about transforming newspapers at the Newspaper Association of America convention; he summarized what he had to say in 10 tweets, and Alan Mutter wrote a post about the panel. The moderator, Ken Doctor, wrote a Lab post looking at how long newspapers have left.

— I'll send you off with Jonathan Stray's thoughtful post on rethinking journalism as a system for informing people, rather than just a series of stories. It's a lot to chew on, but a key piece to add to the future-of-news puzzle.

Similar posts: Buy Tramadol No Prescription. Order Flagyl. Tramadol Over The Counter. Purchase Armour. Cheap Retin A no rx. Purchase Glucophage for sale.
Trackbacks from: Bactrim For Sale. Bactrim For Sale. Bactrim For Sale. Bactrim dosage. Ordering Bactrim online. Buy cheap Bactrim no rx.